This company is no longer active
INDEX Stock Overview
Engages in the research and development of pharmaceuticals for immunological diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
InDex Pharmaceuticals Holding AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.55 |
| 52 Week High | SEK 0.93 |
| 52 Week Low | SEK 0.20 |
| Beta | -0.21 |
| 1 Month Change | 35.15% |
| 3 Month Change | 88.28% |
| 1 Year Change | -4.55% |
| 3 Year Change | -63.84% |
| 5 Year Change | -93.87% |
| Change since IPO | -92.20% |
Recent News & Updates
Market Might Still Lack Some Conviction On InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Even After 35% Share Price Boost
Jun 13
Further Upside For InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Shares Could Introduce Price Risks After 26% Bounce
Apr 28Recent updates
Market Might Still Lack Some Conviction On InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Even After 35% Share Price Boost
Jun 13Further Upside For InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Shares Could Introduce Price Risks After 26% Bounce
Apr 28We're Keeping An Eye On InDex Pharmaceuticals Holding's (STO:INDEX) Cash Burn Rate
Jul 11We Think InDex Pharmaceuticals Holding (STO:INDEX) Can Afford To Drive Business Growth
Jan 21We Think InDex Pharmaceuticals Holding (STO:INDEX) Can Afford To Drive Business Growth
Aug 31Here's Why We're Watching InDex Pharmaceuticals Holding's (STO:INDEX) Cash Burn Situation
Mar 29InDex Pharmaceuticals Holding's (STO:INDEX) Shareholders Are Down 24% On Their Investment Over The Past Year.
Feb 04
How Much Are InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Insiders Spending On Buying Shares?
Dec 21Shareholder Returns
| INDEX | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | 1.1% | 1.3% | 0.7% |
| 1Y | -4.5% | -3.5% | 4.5% |
Return vs Industry: INDEX underperformed the Swedish Pharmaceuticals industry which returned 88.4% over the past year.
Return vs Market: INDEX underperformed the Swedish Market which returned 14.1% over the past year.
Price Volatility
| INDEX volatility | |
|---|---|
| INDEX Average Weekly Movement | 7.5% |
| Pharmaceuticals Industry Average Movement | 9.0% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.5% |
| 10% least volatile stocks in SE Market | 3.2% |
Stable Share Price: INDEX's share price has been volatile over the past 3 months.
Volatility Over Time: INDEX's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 4 | Jenny Sundqvist | www.indexpharma.com |
InDex Pharmaceuticals Holding AB (publ) engages in the research and development of pharmaceuticals for immunological diseases. The company was founded in 2000 and is headquartered in Solna, Sweden.
InDex Pharmaceuticals Holding AB (publ) Fundamentals Summary
| INDEX fundamental statistics | |
|---|---|
| Market cap | SEK 286.59m |
| Earnings (TTM) | -SEK 56.48m |
| Revenue (TTM) | SEK 108.34m |
2.7x
P/S Ratio-5.1x
P/E RatioIs INDEX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INDEX income statement (TTM) | |
|---|---|
| Revenue | SEK 108.34m |
| Cost of Revenue | SEK 4.03m |
| Gross Profit | SEK 104.31m |
| Other Expenses | SEK 160.79m |
| Earnings | -SEK 56.48m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 20, 2024
| Earnings per share (EPS) | -0.11 |
| Gross Margin | 96.28% |
| Net Profit Margin | -52.13% |
| Debt/Equity Ratio | 0% |
How did INDEX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/06/10 11:12 |
| End of Day Share Price | 2024/06/10 00:00 |
| Earnings | 2024/03/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
InDex Pharmaceuticals Holding AB (publ) is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Arvid Necander | Carnegie Investment Bank AB |
| Filip Einarsson | Redeye |